SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation (SCARLET-AF)
Atrial Fibrillation
About this trial
This is an interventional treatment trial for Atrial Fibrillation focused on measuring Atrial fibrillation, Catheter ablation
Eligibility Criteria
Ages eligible for the study: 19 years or older Inclusion criteria: Patients with symptomatic persistent AF who undergo AF catheter ablation due to continued AF even after anti-arrhythmic agents or Patients with a burden of LA LVA (scar zone) of 1cm2 or more and less than 30% in 3D voltage mapping before the index catheter ablation are included in the randomized assignment group when performing catheter ablation in satisfaction with 1) 4) Patients with an LVA of <1cm2 or ≥30% are recruited as a registry. Exclusion criteria: Patients with LA anteroposterior diameter of more than 55 mm Patients with prior AF-related catheter ablation or surgery Patients whose exact LVA burden cannot be calculated because high-quality 3D voltage mapping cannot be obtained during the procedure. Inability or unwillingness to receive anticoagulation (heparin or oral anticoagulation) Known severe left ventricular systolic dysfunction (ejection fraction <35%) Patients with severe structural heart disease (severe mitral regurgitation, hypertrophy cardiomyopathy, other severe valvular heart diseases) Patients with intracardiac thrombus Patients with prior cardiac surgery Patients who had a myocardial infarction or underwent percutaneous coronary intervention within three months Patients who had a stroke or transient ischemic attack within 6 months Patients who had a planned operation or procedure for the cardiovascular system Patients with intractable hypertension or uncontrolled thyroid disease Patients who need dialysis due to end-stage renal disease or who are scheduled for dialysis Patients who are currently pregnant or are likely to be pregnant within the study period Patients who are taking immunosuppressive drugs or had undergone chemotherapy for cancer, autoimmune disease, transplant, etc Patients whose life expectancy is less than 1 year
Sites / Locations
- Seoul National University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
PVI only group
Additional LA substrate modification group
Patients will receive PVI alone regardless of LVA burden.
Patients will receive PVI plus additional LA substrate modification according to their LVA burden.